ABIOMED, Inc. (ABMD)
(Delayed Data from NSDQ)
$307.60 USD
-17.71 (-5.44%)
Updated Mar 3, 2021 04:00 PM ET
This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
| Zacks Rank | Definition | Annualized Return |
|---|---|---|
| 1 | Strong Buy | 24.41% |
| 2 | Buy | 17.88% |
| 3 | Hold | 9.48% |
| 4 | Sell | 5.03% |
| 5 | Strong Sell | 1.87% |
| S&P | 500 | 10.70% |
Zacks Rank Education - Learn about the Zacks Rank
Zacks Rank Home - Zacks Rank resources in one place
Zacks Premium - The only way to fully access the Zacks Rank
3-Hold of 5 3
The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.
The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.
| Value Score | A |
|---|---|
| Growth Score | A |
| Momentum Score | A |
| VGM Score | A |
Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.
As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.
Zacks Style Scores Education - Learn more about the Zacks Style Scores
D Value C Growth B Momentum C VGM
The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.
An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.
The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.
Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank
Company Summary
Headquartered in Danvers, MA and founded in 1981, ABIOMED Inc. (ABMD) is engaged in developing, manufacturing and marketing of medical products, designed to assist or replace the pumping function of the failing heart. Abiomed’s main product line - Impella - comprises Impella 2.5, Impella 5.0, Impella LD, Impella CP and Impella RP.
Impella 2.5 is primarily used by interventional cardiologists to support patients in the cardiac catheterization lab (cath lab) for partial circulatory support for up to six hours.
The Impella 5.0 and Impella LD received 510(K) clearances for circulatory support for up to six ...
Company Summary
Headquartered in Danvers, MA and founded in 1981, ABIOMED Inc. (ABMD) is engaged in developing, manufacturing and marketing of medical products, designed to assist or replace the pumping function of the failing heart. Abiomed’s main product line - Impella - comprises Impella 2.5, Impella 5.0, Impella LD, Impella CP and Impella RP.
Impella 2.5 is primarily used by interventional cardiologists to support patients in the cardiac catheterization lab (cath lab) for partial circulatory support for up to six hours.
The Impella 5.0 and Impella LD received 510(K) clearances for circulatory support for up to six hours. These devices are primarily used in the heart surgery suite and support patients who require higher levels of circulatory support as compared to the Impella 2.5. This equipment can pump up to 5 liters of blood per minute. Impella CP provides blood flow of approximately one liter more per minute than Impella 2.5. Impella RP is a catheter-based axial flow device that can pump more than four liters of blood per minute during right heart failure.
Fiscal 2020: For fiscal 2020, the company's adjusted earnings came in at $4.44, down 12.9% from the year-ago period. Total revenues came in at $840.9 million, which climbed 9.3% year over year.
General Information
ABIOMED, Inc.
22 CHERRY HILL DR
DANVERS, MA 01923
Phone: 978-646-1400
Fax: 978-777-8411
Email: ir@abiomed.com
| Industry | Medical - Instruments |
| Sector | Medical |
| Fiscal Year End | March |
| Last Reported Quarter | 12/31/2020 |
| Next EPS Date | 4/29/2021 |
EPS Information
| Current Quarter EPS Consensus Estimate | 1.11 |
| Current Year EPS Consensus Estimate | 4.81 |
| Estimated Long-Term EPS Growth Rate | 20.50 |
| Next EPS Report Date | 4/29/2021 |
Price and Volume Information
| Zacks Rank |  |
| Yesterday's Close | 325.31 |
| 52 Week High | 387.40 |
| 52 Week Low | 119.01 |
| Beta | 1.37 |
| 20 Day Moving Average | 314,605.34 |
| Target Price Consensus | 328.00 |
| 4 Week | -6.48 |
| 12 Week | 18.88 |
| YTD | 0.34 |
| 4 Week | -7.54 |
| 12 Week | 13.72 |
| YTD | -2.62 |
| Shares Outstanding (millions) | 45.23 |
| Market Capitalization (millions) | 14,714.09 |
| Short Ratio | NA |
| Last Split Date | 10/2/2000 |
| Dividend Yield | 0.00% |
| Annual Dividend | $0.00 |
| Payout Ratio | 0.00 |
| Change in Payout Ratio | 0.00 |
| Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
| P/E (F1) | 67.68 |
| Trailing 12 Months | 86.52 |
| PEG Ratio | 3.30 |
| vs. Previous Year | 5.41% |
| vs. Previous Quarter | 15.84% |
| vs. Previous Year | 4.55% |
| vs. Previous Quarter | 10.44% |
| Price/Book | 11.66 |
| Price/Cash Flow | 61.69 |
| Price / Sales | 18.10 |
| 12/31/20 | 14.86 |
| 9/30/20 | 15.34 |
| 6/30/20 | 16.17 |
| 12/31/20 | 13.12 |
| 9/30/20 | 13.51 |
| 6/30/20 | 14.21 |
| 12/31/20 | 5.76 |
| 9/30/20 | 6.81 |
| 6/30/20 | 5.61 |
| 12/31/20 | 5.08 |
| 9/30/20 | 6.02 |
| 6/30/20 | 4.81 |
| 12/31/20 | 21.07 |
| 9/30/20 | 21.00 |
| 6/30/20 | 21.31 |
| 12/31/20 | 24.66 |
| 9/30/20 | 25.89 |
| 6/30/20 | 19.88 |
| 12/31/20 | 31.25 |
| 9/30/20 | 33.67 |
| 6/30/20 | 26.91 |
| 12/31/20 | 27.89 |
| 9/30/20 | 26.17 |
| 6/30/20 | 24.46 |
| 12/31/20 | 1.80 |
| 9/30/20 | 1.74 |
| 6/30/20 | 1.67 |
| 12/31/20 | 0.00 |
| 9/30/20 | 0.00 |
| 6/30/20 | 0.00 |
| 12/31/20 | 0.00 |
| 9/30/20 | 0.00 |
| 6/30/20 | 0.00 |